5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity
Open Access
- 26 July 2018
- journal article
- research article
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 71 (11) , 950-961
Abstract
5-aminosalicylate (5-ASA) is widely prescribed for the treatment of inflammatory bowel disease (IBD) and prevention of inflammation-associated colorectal cancer (CRC). Its clinical effect is widely attributed to modulation of host inflammatory responses. However, the recent association of intestinal dysbiosis and selective enrichment in Escherichia coli in patients with IBD and CRC raises the possibility that 5-ASA might also affect the enteric microflora. The aim of this study was to investigate the effect of 5-ASA on the growth and virulence of E. coli associated with IBD and CRC, and its impact on host cell inflammatory responses. Our results show that 5-ASA inhibited E. coli growth in a dose-dependent manner and downregulated the expression of bacterial virulence genes associated with IBD (fliC, fimH, ompC, yfgL, nlpL, lpfA, htrA, dsbA, fyuA, and chuA) and CRC (pks). 5-ASA inhibited E. coli motility (30–70%), epithelial adherence and invasion, and IL-8 secretion (p < 0.05). 5-ASA reduced E. coli survival in J774A.1 macrophages by 20 to 50% (p < 0.01) and TNF-α secretion by infected macrophages up to 30% (p < 0.05). In addition, 5-ASA reduced DNA damage in epithelial cells (Caco-2) induced by pks-positive E. coli. Our results reveal a multifaceted and previously unrecognized effect of 5-ASA on the growth and virulence of IBD- and CRC-associated E. coli, in addition to its inhibitory effect on host cell inflammatory responses. These results suggest that 5-ASA may abrogate the proinflammatory and oncogenic effects of E. coli in patients with IBD and CRC.Keywords
Funding Information
- The Roberts IBD Center, Weill-Cornell Medical College, 71st and York, New York, NY.
This publication has 51 references indexed in Scilit:
- High Prevalence of Mucosa-Associated E. coli Producing Cyclomodulin and Genotoxin in Colon CancerPLOS ONE, 2013
- Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB , and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux PumpsAntimicrobial Agents and Chemotherapy, 2013
- Intestinal Inflammation Targets Cancer-Inducing Activity of the MicrobiotaScience, 2012
- NFκB and AP-1 Drive Human Myometrial IL8 ExpressionMediators of Inflammation, 2012
- Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cellsProceedings of the National Academy of Sciences, 2010
- The Nuclear Factor NF- B Pathway in InflammationCold Spring Harbor Perspectives in Biology, 2009
- Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileumThe ISME Journal, 2007
- The Oxidoreductase DsbA Plays a Key Role in the Ability of the Crohn's Disease-Associated Adherent-Invasive Escherichia coli Strain LF82 To Resist Macrophage KillingJournal of Bacteriology, 2007
- On the Action of 5-Amino-Salicylic Acid and Sulfapyridine on M. avium including Subspecies paratuberculosisPLOS ONE, 2007
- Adherent and InvasiveEscherichia coliIs Associated with Granulomatous Colitis in Boxer DogsInfection and Immunity, 2006